Abstract
Meeting abstracts The presence of monosomy 3 in the primary tumor is widely accepted as the most reliable prognostic parameter, identified in approximately 50% of patients with primary uveal melanoma [[1][1]]. Long term studies have shown a 3-year survival rate of 40% if monosomy 3 is present,
Cite
CITATION STYLE
APA
Bol, K., van den Bosch, T., Schreibelt, G., Punt, C., Figdor, C., Paridaens, D., & de Vries, J. (2015). Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients. Journal for ImmunoTherapy of Cancer, 3(S2). https://doi.org/10.1186/2051-1426-3-s2-p127
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free